Update in vitamin D and multiple sclerosis

References

1. ↵
   1. Awad AM,
   2. Stüve O

   (2010) Immunopathogenesis of multiple sclerosis: new insights and therapeutic implications. Continuum (Minneap Minn) 16, 166–180.
2. ↵
   1. Browne P,
   2. Chandraratna D,
   3. Angood C,
   4. Tremlett H,
   5. Baker C,
   6. Taylor BV

   (2014) Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology 83, 1022–1024.
3. ↵
   1. Kurtzke JF

   (1975) A reassessment of the distribution of multiple sclerosis. Acta Neurol Scand 51, 137–157.
4. ↵
   1. Bohlega S,
   2. Inshasi J,
   3. Tahan Al AR,
   4. Madani AB,
   5. Qahtani H,
   6. Rieckmann P

   (2013) Multiple sclerosis in the Arabian Gulf countries: a consensus statement. J Neurol 260, 2959–2963.
5. ↵
   1. Ramagopalan SV,
   2. Dobson R,
   3. Meier UC,
   4. Giovannoni G

   (2010) Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 9, 727–739.
6. ↵
   1. Holick MF

   (2007) Vitamin D deficiency. N Engl J Med 357, 266–281.
7. ↵
   1. Hussain AN,
   2. Alkhenizan AH,
   3. El Shaker M,
   4. Raef H,
   5. Gabr A

   (2014) Increasing trends and significance of hypovitaminosis D: a population-based study in the Kingdom of Saudi Arabia. Arch Osteoporos 9, 190.
8. ↵
   1. Vieth R

   (1999) Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 69, 842–856.
9. ↵
   1. Bikle DD

   (2014) Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol 21, 319–329.
10. ↵
    1. Christakos S,
    2. Ajibade DV,
    3. Dhawan P,
    4. Fechner AJ,
    5. Mady LJ

    (2010) Vitamin D: metabolism. Endocrinol Metab Clin North Am 39, 243–253.
11. ↵
    1. Hollis BW

    (1996) Assessment of vitamin D nutritional and hormonal status: what to measure and how to do it. Calcif Tissue Int 58, 4–5.
12. ↵
    1. Hanwell HE,
    2. Banwell B

    (2011) Assessment of evidence for a protective role of vitamin D in multiple sclerosis. Biochim Biophys Acta 1812, 202–212.
13. ↵
    1. Trochoutsou A,
    2. Kloukina V,
    3. Samitas K,
    4. Xanthou G

    (2015) Vitamin-D in the Immune System: Genomic and Non-Genomic Actions. Mini Rev Med Chem 15, 953–963.
14. ↵
    1. Provvedini DM,
    2. Tsoukas CD,
    3. Deftos LJ,
    4. Manolagas SC

    (1983) 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 221, 1181–1183.
15. ↵
    1. Garcion E,
    2. Wion-Barbot N,
    3. Montero-Menei CN,
    4. Berger F,
    5. Wion D

    (2002) New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 13, 100–105.
16. ↵
    1. Gottfried E,
    2. Rehli M,
    3. Hahn J,
    4. Holler E,
    5. Andreesen R,
    6. Kreutz M

    (2006) Monocyte-derived cells express CYP27A1 and convert vitamin D3 into its active metabolite. Biochem Biophys Res Commun 349, 209–213.
17. ↵
    1. van Etten E,
    2. Mathieu C

    (2005) Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 97, 93–101.
18. ↵
    1. Aranow C

    (2011) Vitamin D and the immune system. J Investig Med 59, 881–886.
19. ↵
    1. Scolletta S,
    2. Colletti M,
    3. Di Luigi L,
    4. Crescioli C

    (2013) Vitamin D receptor agonists target CXCL10: new therapeutic tools for resolution of inflammation. Mediators Inflamm 2013, 876319.
20. ↵
    1. Simpson S Jr.,
    2. Blizzard L,
    3. Otahal P,
    4. Van der Mei I,
    5. Taylor B

    (2011) Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 82, 1132–1141.
21. ↵
    1. Mansouri B,
    2. Asadollahi S,
    3. Heidari K,
    4. Fakhri M,
    5. Assarzadegan F,
    6. Nazari M,
    7. et al.

    (2014) Risk factors for increased multiple sclerosis susceptibility in the Iranian population. J Clin Neurosci 21, 2207–2211.
22. 1. Bjørnevik K,
    2. Riise T,
    3. Casetta I,
    4. Drulovic J,
    5. Granieri E,
    6. Holmøy T,
    7. et al.

    (2014) Sun exposure and multiple sclerosis risk in Norway and Italy: The EnvIMS study. Mult Scler 20, 1042–1049.
23. 1. Islam T,
    2. Gauderman WJ,
    3. Cozen W,
    4. Mack TM

    (2007) Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 69, 381–388.
24. ↵
    1. Lucas RM,
    2. Ponsonby AL,
    3. Dear K,
    4. Valery PC,
    5. Pender MP,
    6. Taylor BV,
    7. et al.

    (2011) Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 76, 540–548.
25. 1. van der Mei IA,
    2. Ponsonby AL,
    3. Dwyer T,
    4. Blizzard L,
    5. Simmons R,
    6. Taylor BV,
    7. et al.

    (2003) Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 327, 316.
26. ↵
    1. Bäärnhielm M,
    2. Hedström AK,
    3. Kockum I,
    4. Sundqvist E,
    5. Gustafsson SA,
    6. Hillert J,
    7. et al.

    (2012) Sunlight is associated with decreased multiple sclerosis risk: no interaction with human leukocyte antigen-DRB1*15. Eur J Neurol 19, 955–962.
27. ↵
    1. Dobson R,
    2. Giovannoni G,
    3. Ramagopalan S

    (2013) The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude. J Neurol Neurosurg Psychiatry 84, 427–432.
28. ↵
    1. Norval M,
    2. Halliday GM

    (2011) The consequences of UV-induced immunosuppression for human health. Photochem Photobiol 87, 965–977.
29. ↵
    1. Wang Y,
    2. Marling SJ,
    3. Beaver EF,
    4. Severson KS,
    5. Deluca HF

    (2015) UV light selectively inhibits spinal cord inflammation and demyelination in experimental autoimmune encephalomyelitis. Arch Biochem Biophys 567, 75–82.
30. ↵
    1. Becklund BR,
    2. Severson KS,
    3. Vang SV,
    4. DeLuca HF

    (2010) UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc Natl Acad Sci U S A 107, 6418–6423.
31. ↵
    1. Munger KL,
    2. Levin LI,
    3. Hollis BW,
    4. Howard NS,
    5. Ascherio A

    (2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296, 2832–2838.
32. ↵
    1. Salzer J,
    2. Hallmans G,
    3. Nyström M,
    4. Stenlund H,
    5. Wadell G,
    6. Sundström P

    (2012) Vitamin D as a protective factor in multiple sclerosis. Neurology 79, 2140–2145.
33. ↵
    1. Munger KL,
    2. Zhang SM,
    3. O'Reilly E,
    4. Hernán MA,
    5. Olek MJ,
    6. Willett WC,
    7. et al.

    (2004) Vitamin D intake and incidence of multiple sclerosis. Neurology 62, 60–65.
34. ↵
    1. Kampman MT,
    2. Wilsgaard T,
    3. Mellgren SI

    (2007) Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol 254, 471–477.
35. ↵
    1. Bäärnhielm M,
    2. Olsson T,
    3. Alfredsson L

    (2014) Fatty fish intake is associated with decreased occurrence of multiple sclerosis. Mult Scler 20, 726–732.
36. ↵
    1. Mirzaei F,
    2. Michels KB,
    3. Munger K,
    4. O'Reilly E,
    5. Chitnis T,
    6. Forman MR,
    7. et al.

    (2011) Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann Neurol 70, 30–40.
37. ↵
    1. Munger KL,
    2. Chitnis T,
    3. Frazier AL,
    4. Giovannucci E,
    5. Spiegelman D,
    6. Ascherio A

    (2011) Dietary intake of vitamin D during adolescence and risk of multiple sclerosis. J Neurol 258, 479–485.
38. ↵
    1. Ueda P,
    2. Rafatnia F,
    3. Bäärnhielm M,
    4. Fröbom R,
    5. Korzunowicz G,
    6. Lönnerbro R,
    7. et al.

    (2014) Neonatal vitamin D status and risk of multiple sclerosis. Ann Neurol 76, 338–346.
39. ↵
    1. Pandit L,
    2. Ramagopalan SV,
    3. Malli C,
    4. D'Cunha A,
    5. Kunder R,
    6. Shetty R

    (2013) Association of vitamin D and multiple sclerosis in India. Mult Scler 19, 1592–1296.
40. 1. Neau JP,
    2. Artaud-Uriot MS,
    3. Lhomme V,
    4. Bounaud JY,
    5. Lebras F,
    6. Boissonnot L,
    7. et al.

    (2011) [Vitamin D and multiple sclerosis. A prospective survey of patients of Poitou-Charentes area]. Rev Neurol (Paris) 167, 317–323, French.
41. ↵
    1. Shahbeigi S,
    2. Pakdaman H,
    3. Fereshtehnejad SM,
    4. Nikravesh E,
    5. Mirabi N,
    6. Jalilzadeh G

    (2013) Vitamin d3 concentration correlates with the severity of multiple sclerosis. Int J Prev Med 4, 585–591.
42. 1. Mazdeh M,
    2. Seifirad S,
    3. Kazemi N,
    4. Seifrabie MA,
    5. Dehghan A,
    6. Abbasi H

    (2013) Comparison of vitamin D3 serum levels in new diagnosed patients with multiple sclerosis versus their healthy relatives. Acta Med Iran 51, 289–292.
43. 1. Kubicka K,
    2. Pierzchała K

    (2013) Concentration of 25(OH)D₃ and calcium and phosphorus metabolism in patients suffering from relapsing-remitting multiple sclerosis. A pilot study. Neurol Neurochir Pol 47, 126–130.
44. ↵
    1. Yildiz M,
    2. Tettenborn B,
    3. Putzki N

    (2011) Vitamin D levels in Swiss multiple sclerosis patients. Swiss Med Wkly 141, w13192.
45. ↵
    1. Martinelli V,
    2. Dalla Costa G,
    3. Colombo B,
    4. Dalla Libera D,
    5. Rubinacci A,
    6. Filippi M,
    7. et al.

    (2014) Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler 20, 147–155.
46. ↵
    1. Simpson S Jr.,
    2. Taylor B,
    3. Blizzard L,
    4. Ponsonby AL,
    5. Pittas F,
    6. Tremlett H,
    7. et al.

    (2010) Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 68, 193–203.
47. ↵
    1. Mowry EM,
    2. Krupp LB,
    3. Milazzo M,
    4. Chabas D,
    5. Strober JB,
    6. Belman AL,
    7. et al.

    (2010) Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 67, 618–624.
48. 1. Runia TF,
    2. Hop WC,
    3. de Rijke YB,
    4. Buljevac D,
    5. Hintzen RQ

    (2012) Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 79, 261–266.
49. ↵
    1. Smolders J,
    2. Menheere P,
    3. Kessels A,
    4. Damoiseaux J,
    5. Hupperts R

    (2008) Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 14, 1220–1224.
50. 1. van der Mei IA,
    2. Ponsonby AL,
    3. Dwyer T,
    4. Blizzard L,
    5. Taylor BV,
    6. Kilpatrick T,
    7. et al.

    (2007) Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 254, 581–590.
51. 1. Weinstock-Guttman B,
    2. Zivadinov R,
    3. Qu J,
    4. Cookfair D,
    5. Duan X,
    6. Bang E,
    7. et al.

    (2011) Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 82, 189–195.
52. ↵
    1. Harandi AA,
    2. Shahbeigi S,
    3. Pakdaman H,
    4. Fereshtehnejad SM,
    5. Nikravesh E,
    6. Jalilzadeh R

    (2012) Association of serum 25(OH) vitamin D3 concentration with severity of multiple sclerosis. Iran J Neurol 11, 54–58.
53. ↵
    1. Thouvenot E,
    2. Orsini M,
    3. Daures JP,
    4. Camu W

    (2015) Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis. Eur J Neurol 22, 564–569.
54. ↵
    1. Ascherio A,
    2. Munger KL,
    3. White R,
    4. Köchert K,
    5. Simon KC,
    6. Polman CH,
    7. et al.

    (2014) Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 71, 306–314.
55. ↵
    1. Mosayebi G,
    2. Ghazavi A,
    3. Ghasami K,
    4. Jand Y,
    5. Kokhaei P

    (2011) Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest 40, 627–639.
56. 1. Wingerchuk DM,
    2. Lesaux J,
    3. Rice GP,
    4. Kremenchutzky M,
    5. Ebers GC

    (2005) A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 76, 1294–1296.
57. 1. Soilu-Hänninen M,
    2. Aivo J,
    3. Lindström BM,
    4. Elovaara I,
    5. Sumelahti ML,
    6. Färkkilä M,
    7. et al.

    (2012) A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 83, 565–571.
58. 1. Kimball S,
    2. Vieth R,
    3. Dosch HM,
    4. Bar-Or A,
    5. Cheung R,
    6. Gagne D,
    7. et al.

    (2011) Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. J Clin Endocrinol Metab 96, 2826–2834.
59. 1. Shaygannejad V,
    2. Janghorbani M,
    3. Ashtari F,
    4. Dehghan H

    (2012) Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult Scler Int 2012, 452541.
60. 1. Stein MS,
    2. Liu Y,
    3. Gray OM,
    4. Baker JE,
    5. Kolbe SC,
    6. Ditchfield MR,
    7. et al.

    (2011) A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 77, 1611–1618.
61. 1. Burton JM,
    2. Kimball S,
    3. Vieth R,
    4. Bar-Or A,
    5. Dosch HM,
    6. Cheung R,
    7. et al.

    (2010) A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 74, 1852–1859.
62. 1. Derakhshandi H,
    2. Etemadifar M,
    3. Feizi A,
    4. Abtahi SH,
    5. Minagar A,
    6. Abtahi MA,
    7. et al.

    (2013) Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial. Acta Neurol Belg 113, 257–263.
63. 1. Kampman MT,
    2. Steffensen LH,
    3. Mellgren SI,
    4. Jørgensen L

    (2012) Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler 18, 1144–1151.
64. 1. Mahon BD,
    2. Gordon SA,
    3. Cruz J,
    4. Cosman F,
    5. Cantorna MT

    (2003) Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 134, 128–132.
65. 1. Smolders J,
    2. Peelen E,
    3. Thewissen M,
    4. Cohen Tervaert JW,
    5. Menheere P,
    6. Hupperts R,
    7. et al.

    (2010) Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One 5, e15235.
66. ↵
    1. Knippenberg S,
    2. Smolders J,
    3. Thewissen M,
    4. Peelen E,
    5. Tervaert JW,
    6. Hupperts R,
    7. et al.

    (2011) Effect of vitamin D(3) supplementation on peripheral B cell differentiation and isotype switching in patients with multiple sclerosis. Mult Scler 17, 1418–1423.
67. ↵
    1. Ascherio A,
    2. Munger KL,
    3. Simon KC

    (2010) Vitamin D and multiple sclerosis. Lancet Neurol 9, 599–612.
68. ↵
    (2011) International Multiple Sclerosis Genetics Consortium;Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214–219.
69. ↵
    1. Cree BA

    (2014) Multiple sclerosis genetics. Handb Clin Neurol 122, 193–209.
70. ↵
    1. Hearn AP,
    2. Silber E

    (2010) Osteoporosis in multiple sclerosis. Mult Scler 16, 1031–1043.
71. ↵
    1. Ross AC,
    2. Manson JE,
    3. Abrams SA,
    4. Aloia JF,
    5. Brannon PM,
    6. Clinton SK,
    7. et al.

    (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96, 53–58.